Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxin Dawaiyimisike Migao is a traditional Uyghur medicine formulated as a brown, viscous honey paste with a unique aroma and a sweet, slightly bitter taste. It is manufactured by Xinjiang Uygur Pharmaceutical Co., Ltd. and holds the National Medical Product Approval Number Z65020175, indicating its status as an approved pharmaceutical drug in China. The drug is composed of numerous natural ingredients, including sandalwood, red sandalwood, artificial musk, saffron, bamboo sugar, frankincense, borage flower, silkworm cocoon, pearl, agarwood, gold leaf, silver leaf, cinnamon, heguoteng, apple, emblic, dracocephalum moldavica, purslane seed, amber, usnea, centaurea cyanus root, coriander seed, rose flower, cardamom, berberis fruit, and limonium gmelinii. Traditionally, it is used to enhance the function of dominant organs, strengthen the stomach, and refresh the mind. Its primary indications include chest pain, palpitations, stomach weakness, blurred vision, and neurasthenia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yangxin Dawaiyimisike Migao.